Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

INCHEON, Korea--(BUSINESS WIRE)-- #Biosimilar--Samsung Bioepis Co., Ltd. today announced the launch of OBODENCEâ"¢ (60 mg pre-filled syringe) and XBRYKâ"¢ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. "We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability ch ...